Literature DB >> 16842373

Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.

L D Lewis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16842373      PMCID： PMC1885080          DOI： 10.1111/j.1365-2125.2006.02721.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  29 in total

1.  Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

Review 3.  Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Authors:  Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

4.  Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

Authors:  H Schmidli; B Peng; G-J Riviere; R Capdeville; M Hensley; I Gathmann; A E Bolton; A Racine-Poon
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

5.  Selective toxicity.

Authors:  A ALBERT
Journal:  Nature       Date:  1950-01-07       Impact factor: 49.962

Review 6.  [Oncology].

Authors:  R Osieka
Journal:  Arzneimittelforschung       Date:  1997-10

Review 7.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

8.  New targets and challenges in the molecular therapeutics of cancer.

Authors:  Alan Eastman; Raymond P Perez
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

9.  Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

Authors:  Carlo Gambacorti-Passerini; Massimo Zucchetti; Domenico Russo; Roberta Frapolli; Magda Verga; Silvia Bungaro; Lucia Tornaghi; Fabio Rossi; Pietro Pioltelli; Enrico Pogliani; Daniele Alberti; Gianmarco Corneo; Maurizio D'Incalci
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

10.  Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

Authors:  René Bruno; Robert Olivares; Jocelyne Berille; Philip Chaikin; Nicole Vivier; Luz Hammershaimb; Gerald R Rhodes; James R Rigas
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531
View more
  7 in total

Review 1.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

2.  Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.

Authors:  Lionel D Lewis
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

3.  What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 4.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

5.  New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling.

Authors:  Mikael P Johansson; Hannu Maaheimo; Filip S Ekholm
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

6.  Increasing the Potential of the Auristatin Cancer-Drug Family by Shifting the Conformational Equilibrium.

Authors:  Iris K Sokka; Filip S Ekholm; Mikael P Johansson
Journal:  Mol Pharm       Date:  2019-06-28       Impact factor: 4.939

7.  Access to innovative cancer medicines in a middle-income country - the case of Mexico.

Authors:  Daniela Moye-Holz; Rene Soria Saucedo; Jitse P van Dijk; Sijmen A Reijneveld; Hans V Hogerzeil
Journal:  J Pharm Policy Pract       Date:  2018-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.